A buying checklist for hospital and health system leaders evaluating remote prenatal ultrasound, with Pulsenmore ES as a worked example.

TL;DR
- A hospital should ask seven questions before investing in remote ultrasound, starting with who acquires the images.
- The AMA’s Digital Health Implementation Playbook lists six vendor evaluation variables: return on investment, IT integration, HIPAA compliance and security, user experience, customer service, and documented clinical outcomes.
- Remote ultrasound comes in two categories, clinician-operated handheld devices and patient-operated home systems, and the questions differ for each.
- A pilot with defined measures comes before a wider rollout, because proving clinical results can take six months or longer.
- Pulsenmore ES is a physician-prescribed home prenatal ultrasound system with FDA De Novo marketing authorization, and it answers each of these questions directly.
This checklist is for hospital and health system leaders deciding whether a remote prenatal ultrasound system fits their care model. Each of the seven questions below is followed by what Pulsenmore ES offers, so the answers can be compared with any other vendor. The first step is to identify who acquires the images. Clinician-operated handheld probes and patient-operated home systems serve different care pathways, and each has its own evidence and workflow questions.
1. Does the authorized use match your use case?
Ask for the regulatory status, the indicated population, and the stated limits. The FDA granted De Novo marketing authorization for Pulsenmore ES in an announcement dated November 3, 2025, for use in singleton pregnancies between 14 and 38 weeks of gestation, including fetal heart rate determination interpreted by healthcare professionals.
2. What evidence applies to your patients?
Ask for peer-reviewed studies, the sponsor of each, and the population studied. In a study of 100 women in Israel, fetal cardiac activity was detected in 95.3 percent of scans. The multicenter U.S. HOLA study, which supported the FDA authorization, evaluated 162 women at four institutions across 1,370 scans, with successful fetal cardiac activity assessment in 99.2 percent of clinician-guided and 96.5 percent of app-guided scans. A retrospective cohort of 4,460 users and 102,707 matched non-users found no significant association with preterm delivery or adverse neonatal outcomes, and a randomized trial in women with recurrent pregnancy loss reported lower anxiety. An independent German study reported lower success rates across two mobile systems, which shows why a hospital should ask which device and mode each result covers.
3. Who reviews scans, and how does the workflow run?
Ask who reads each scan, how quickly, and what happens when a finding is abnormal. The Pulsenmore platform allows for role-based workflows. An administrator can schedule appointments, while a sonographer or midwife reviews scans and records their findings. The doctor then provides the final sign-off. This workflow helps free up doctors’ time, allowing them to focus on patients who need to be seen face to face. Review capacity is a staffing decision for the hospital, so it belongs in the plan before launch. Sheba Medical Center’s hospital-at-home program for high-risk pregnancy shows a hospital placing home ultrasound inside a larger remote care workflow.
4. How does it connect to your electronic medical record?
Ask how scan data reaches the record. Pulsenmore supports secure access to scan data that can be referenced or documented in the EMR according to institutional policies.
5. How is patient data protected?
Pulsenmore’s data management document lists ISO 27001 and ISO 27799 compliance and says pseudonymized scans are stored on Azure. The teleconsultation platform is HIPAA compliant. A hospital should still request a business associate agreement and its own security review.
6. What support does the vendor provide?
Ask how the program is set up, how staff are trained, and who answers support questions. Pulsenmore works closely with each organization to understand its clinical needs, develop an appropriate care model, and support implementation. Providers should also assess connectivity and smartphone compatibility: app-guided scans need no live session, but internet connectivity is still required to transmit scans for review.
7. How will you measure success?
The AMA playbook tells teams to define success early and to start with a small pilot, and it notes that clinical results can take six months or longer to show.
The seven questions at a glance
| Question | What to request | Pulsenmore ES information | To confirm with the vendor |
| 1. Authorized use | Indication and limits | FDA De Novo; 14 to 38 weeks; singleton | Fit with your patient mix |
| 2. Evidence | Studies and sponsors | Feasibility, accuracy, outcomes, and patient experience studies | Studies for your population |
| 3. Scan review | Reviewer and timing | Role-based workflow with physician sign-off | Your staffing model |
| 4. EMR integration | Technical documentation | Scan data can be documented in the EMR | Your EMR connection |
| 5. Data protection | Standards and agreements | ISO 27001, ISO 27799, GDPR | Business associate agreement |
| 6. Support | Onboarding plan | Care model and implementation support | Training, connectivity, and service terms |
Practical Takeaways for decision-makers
First, write down the use case and confirm the authorized use matches it. Second, request the studies, their sponsors, and the populations. Third, name the roles that review scans and the response to an abnormal scan. Fourth, run a security and integration review with the hospital’s own teams. Fifth, define success measures and a pilot before the contract.
Pulsenmore’s review of three years of research and real-world use gives a wider picture of the clinical record.
Teams evaluating home ultrasound can start at Pulsenmore’s home ultrasound page and the Pulsenmore resource center.
FAQs
Q: Does Pulsenmore ES connect to a hospital’s EMR?
A: Pulsenmore supports secure access to scan data that can be referenced or documented in the EMR according to institutional policies. The technical connection depends on the hospital’s system and should be confirmed during evaluation.
Q: How does Pulsenmore protect patient data?
A: The data management document lists ISO 27001 and ISO 27799 compliance, GDPR compliance, and pseudonymized scans stored on Azure. The teleconsultation platform is HIPAA compliant. A hospital should request a business associate agreement.
Q: Who operates the scan, and who reads it?
A: The patient operates the transducer, either alone in app-guided mode or with live clinician direction in clinician-guided mode. Review is role-based: a sonographer or midwife reviews scans and records findings, and a doctor provides the final sign-off.
Q: Which patients is Pulsenmore ES intended for?
A: It is designed for use from week 14 through week 38 in single-fetus pregnancies. A physician prescription is required, and each device is personal and intended for one patient during one pregnancy.
Q: How does a hospital start an evaluation?
A: Healthcare providers and organizations interested in integrating Pulsenmore into their prenatal care programs can contact the company directly through its website. The Pulsenmore team works closely with each organization to understand its clinical needs, develop an appropriate care model, and support implementation. Once the program is established, eligible patients can access home ultrasound as part of their provider’s prenatal care services.
Q: Is Pulsenmore ES available in the United States now?
A: Yes. Pulsenmore launched U.S. commercial operations in 2026, with initial agreements with the Center for Fetal Maternal Ultrasound in Los Angeles and TLC Perinatal Care in Maryland, followed by a partnership with Ouma Health to expand access to remote prenatal care. Healthcare providers interested in offering Pulsenmore home ultrasound can contact the company directly to learn more about the technology and integrate it into their prenatal care services. Once enrolled, eligible patients can purchase the device directly through Pulsenmore’s website with a prescription from their healthcare provider.
Q: How does reimbursement work for Pulsenmore home ultrasound in the U.S.?
A: Pulsenmore can be integrated into existing prenatal care models. Under a common commercial approach, healthcare providers offer the home ultrasound device to patients for a fee and may seek reimbursement from insurers for eligible ultrasound services performed and interpreted by clinicians. Reimbursement depends on the services provided, applicable billing codes, payer policies, and individual coverage arrangements. Pulsenmore works with healthcare organizations to explore clinical and commercial models that fit their practice.